Mivax Therapeutics, Inc. — Form D/A
Mivax Therapeutics, Inc. of SAN FRANCISCO, CA, a company, filed a Form D amendment with the SEC on 2026-01-23. The offering totals $500K, of which $203K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2026-01-23
- Form: D/A
- Accession: 0002066303-26-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $500K
- Amount sold: $203K
- Remaining: $298K
- Minimum investment: $2K
- Investors: 21
- Date of first sale: 2025-04-17
- Security types: equity
- Revenue range: $1 - $1,000,000
- SEC file number: 021-544963
Issuer
- Name: Mivax Therapeutics, Inc.
- CIK: 0002066303
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2024
- Address: 701 CHINA BASIN ST, SAN FRANCISCO, CA, 94158
- Phone: 7857706160
Officers, directors & promoters (4)
| Name | Role | Location |
|---|
| Viraj Balkrishna Deshpande | Executive Officer | San Francisco, CA |
| Viraj Balkrishna Deshpande | Related Person | San Francisco, CA |
| Pragyesh Balkrishna Dhungel | Executive Officer | San Francisco, CA |
| Pragyesh Dhungel | Related Person | San Francisco, CA |
Other filings by this issuer (3)
More